z-logo
open-access-imgOpen Access
Decrease of Atherosclerosis Markers and Oxidative Stress After 1 Year Administration of Omega-3 Fatty Acids Supplements in Patients with Metabolic Syndrome
Author(s) -
Andreea Dragomir,
Emila Rusu,
Mihaela Posea,
Gabriela Radulian
Publication year - 2014
Publication title -
romanian journal of diabetes nutrition and metabolic diseases
Language(s) - English
Resource type - Journals
eISSN - 2284-6417
pISSN - 2068-8245
DOI - 10.2478/rjdnmd-2014-0022
Subject(s) - medicine , oxidative stress , adiponectin , metabolic syndrome , fish oil , endocrinology , leptin , polyunsaturated fatty acid , fatty acid , obesity , fish <actinopterygii> , biochemistry , insulin resistance , biology , fishery
Background and Aims: To assess the impact of 1 year administration of omega-3 fatty acids supplements on oxidative stress parameters and atherosclerosis progression. Material and Methods: A total of 284 patients with metabolic syndrome, aged 61±6.7 years, without clinical evidence of atherosclerosis were allocated to 2 groups, matched by sex and age: group A (140 patients) - diet according to ESC/EASD recommendations; group B (144 patients) - the same diet + capsules of fish oil (1g eicosapentanoic acid, 1g docosahexanoic acid, 0,1g a-tocopherol acetate). Body fat (BF) was measured by bioimpedance analysis. For oxidative stress evaluation we used the FormOx systems monitor on a blood drop and for progression of atherosclerosis the intima-media thickness (IMT) at common carotid artery. Patients were evaluated at baseline, after 6 months and 1 year. Results: IMT significantly decreased in group B vs group A at 1 year (p<0.0001) and was correlated with %BF (p<0.001), waist-to-hip ratio (WHR) (p=0.002), leptin (p< 0.001), adiponectin (p<0.05), leptin/adiponectin ratio (p< 0.001) and oxidative stress (p<0.001). Conclusions: One year administrations of omega-3 PUFA enriched diet reduces cardiovascular risk of metabolic syndrome patients, resulting in a significant decrease of oxidative stress and atherosclerosis progression

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here